The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Insights into the Myeloma XIV/FiTNEss trial: frailty-adjusted therapy in transplant-ineligible NDMM
Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, shares some insights into the Phase III Myeloma XIV (FiTNEss) trial (NCT03720041), which is evaluating whether the IMWG frailty score may be used to dose adapt induction therapy for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
